Qu C, Srivastava K, Ko J, Zhang T F, Sampson H A, Li X-M
Department of Pediatrics, Division of Allergy and Immunology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Clin Exp Allergy. 2007 Jun;37(6):846-55. doi: 10.1111/j.1365-2222.2007.02718.x.
Peanut (PN)-anaphylaxis is potentially life threatening. We previously reported that a Chinese herbal medicine preparation, food allergy herbal formula-2 (FAHF-2), prevented peanut allergy (PNA) in mice when administered during sensitization.
To investigate whether FAHF-2 also can prevent anaphylactic reactions when administered to mice with established PNA and, if so, whether protection would persist after cessation of therapy.
C3H/HeJ mice sensitized and boosted over 8 weeks with a standard protocol known to establish PN hypersensitivity received seven weeks of FAHF-2 treatment or water as a sham treatment. Mice were subsequently challenged with PN at week 14 (1-day post-therapy) and week 18 (4-week post-therapy) to evaluate the efficacy and persistence of FAHF-2 treatment by assessing anaphylactic scores, core body temperatures and plasma histamine levels. Serum PN-specific antibody levels and cytokine profiles from splenocytes and mesenteric lymph node (MLN) cells were also determined.
All sham-treated mice challenged at weeks 14 and 18 showed anaphylactic symptoms. In contrast, FAHF-2-treated mice showed no sign of anaphylactic reactions. PN-specific IgE levels in FAHF-2-treated mice also were reduced whereas IgG2a levels were increased. Furthermore, MLN cells from FAHF-2-treated mice produced markedly less IL-4 and IL-5, but more IFN-gamma, and contained increased numbers of IFN-gamma-producing CD8+ cells as compared with sham-treated mice.
FAHF-2 treatment established PN tolerance in this model, which persisted for at least 4-week post-treatment. This result was associated with modulation of intestinal T helper type 1 cell (Th1) and Th2 cytokine production, and with increased numbers of mesenteric IFN-gamma-producing CD8+ cells.
花生过敏有潜在生命危险。我们之前报道过一种中药制剂,食物过敏中药配方-2(FAHF-2),在致敏期间给予小鼠时可预防花生过敏(PNA)。
研究FAHF-2给予已建立花生过敏的小鼠时是否也能预防过敏反应,若能预防,停止治疗后保护作用是否持续。
用已知可建立花生超敏反应的标准方案致敏并在8周内加强免疫的C3H/HeJ小鼠接受7周的FAHF-2治疗或作为假处理的水。随后在第14周(治疗后1天)和第18周(治疗后4周)用花生对小鼠进行激发,通过评估过敏评分、核心体温和血浆组胺水平来评估FAHF-2治疗的疗效和持续性。还测定了血清中花生特异性抗体水平以及脾细胞和肠系膜淋巴结(MLN)细胞的细胞因子谱。
在第14周和第18周接受激发的所有假处理小鼠均出现过敏症状。相比之下,接受FAHF-2治疗的小鼠未表现出过敏反应迹象。接受FAHF-2治疗的小鼠中花生特异性IgE水平也降低,而IgG2a水平升高。此外,与假处理小鼠相比,接受FAHF-2治疗的小鼠的MLN细胞产生的IL-4和IL-5明显减少,但IFN-γ增多,且产生IFN-γ的CD8+细胞数量增加。
在该模型中,FAHF-2治疗建立了花生耐受性,且在治疗后至少持续4周。这一结果与肠道1型辅助性T细胞(Th1)和Th2细胞因子产生的调节以及肠系膜产生IFN-γ的CD8+细胞数量增加有关。